| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $18,131,933 | 25 | 100 |
| Patel Naimish | Chief Medical Officer | 0 | $0 | 2 | $362,596 | $-362,596 |
| George Simeon | director | 0 | $0 | 1 | $720,373 | $-720,373 |
| Behbahani Ali | director | 0 | $0 | 1 | $780,935 | $-780,935 |
| KASINGER JAMES R. | General Counsel and Secretary | 0 | $0 | 7 | $1.37M | $-1.37M |
| Prasad Raju | Chief Financial Officer | 0 | $0 | 6 | $5.3M | $-5.3M |
| Kulkarni Samarth | Chief Executive Officer | 0 | $0 | 8 | $9.6M | $-9.6M |
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and …
Over the last 12 months, insiders at CRISPR Therapeutics AG have bought $0 and sold $18.13M worth of CRISPR Therapeutics AG stock.
On average, over the past 5 years, insiders at CRISPR Therapeutics AG have bought $53M and sold $11.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $1.14M was made by Treco Douglas A (director) on 2025‑08‑06.
| 2026-10-19 | Sale | Kulkarni Samarth | Chief Executive Officer | 47,837 0.0492% | $49.78 | $2.38M | -0.10% | |
| 2026-10-14 | Sale | Kulkarni Samarth | Chief Executive Officer | 4,098 0.0042% | $49.26 | $201,867 | -0.41% | |
| 2026-10-14 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 1,040 0.0011% | $49.26 | $51,230 | -0.41% | |
| 2026-10-14 | Sale | George Simeon | director | 14,514 0.0148% | $49.63 | $720,373 | -0.41% | |
| 2026-10-06 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 1,990 0.0023% | $60.04 | $119,481 | -6.80% | |
| 2026-09-22 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 10,400 0.0115% | $60.24 | $626,460 | -12.70% | |
| 2026-09-17 | Sale | Behbahani Ali | director | 13,679 0.0141% | $57.09 | $780,935 | -8.68% | |
| 2026-05-29 | Sale | Patel Naimish | Chief Medical Officer | 3,786 0.0039% | $55.62 | $210,577 | -4.97% | |
| 2026-03-23 | Sale | Kulkarni Samarth | Chief Executive Officer | 10,020 0.0104% | $46.78 | $468,736 | +12.37% | |
| 2026-03-23 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 3,182 0.0033% | $46.78 | $148,854 | +12.37% | |
| 2026-03-23 | Sale | Prasad Raju | Chief Financial Officer | 3,708 0.0039% | $46.78 | $173,460 | +12.37% | |
| 2026-03-16 | Sale | Kulkarni Samarth | Chief Executive Officer | 10,349 0.0107% | $48.26 | $499,443 | +8.26% | |
| 2026-03-16 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 3,450 0.0036% | $48.26 | $166,497 | +8.26% | |
| 2026-03-16 | Sale | Prasad Raju | Chief Financial Officer | 9,869 0.0102% | $48.26 | $476,278 | +8.26% | |
| 2026-03-16 | Sale | Patel Naimish | Chief Medical Officer | 3,150 0.0033% | $48.26 | $152,019 | +8.26% | |
| 2026-03-11 | Sale | Kulkarni Samarth | Chief Executive Officer | 9,798 0.0108% | $52.80 | $517,334 | +4.88% | |
| 2026-03-11 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 2,800 0.0031% | $52.80 | $147,840 | +4.88% | |
| 2026-02-19 | Sale | Kulkarni Samarth | Chief Executive Officer | 6,967 0.0071% | $52.58 | $366,325 | -3.34% | |
| 2026-02-19 | Sale | KASINGER JAMES R. | General Counsel and Secretary | 2,112 0.0022% | $52.58 | $111,049 | -3.34% | |
| 2026-01-22 | Sale | Kulkarni Samarth | Chief Executive Officer | 60,000 0.0624% | $60.23 | $3.61M | -13.17% |
| Patel Naimish | Chief Medical Officer | 19357 0.02% | $967,656.43 | 1 | 3 | +64.51% |
| George Simeon | director | 15486 0.016% | $774,145.14 | 2 | 1 | +15.44% |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 5632802 5.8255% | $281.58M | 1 | 0 | +77.06% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 5.565% | $268.99M | 4 | 0 | +63.29% |
| CELGENE CORP /DE/ | 10 percent owner | 4173019 4.3158% | $208.61M | 1 | 21 | +31.44% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 3220627 3.3308% | $161M | 1 | 0 | +31.44% |
| EMSTER KURT VON | director | 1171268 1.2113% | $58.55M | 2 | 39 | +54.25% |
| Woiwode Thomas | director | 640014 0.6619% | $31.99M | 1 | 11 | +31.44% |
| Lundberg Sven Ante | Chief Scientific Officer | 505617 0.5229% | $25.28M | 1 | 0 | +31.44% |
| Bolzon Bradley J PhD | director | 148831 0.1539% | $7.44M | 1 | 30 | +31.44% |
| Versant Venture Capital IV, L.P. | 10 percent owner | 45171 0.0467% | $2.26M | 1 | 1 | +31.44% |
| Treco Douglas A | director | 22000 0.0228% | $1.1M | 1 | 0 | <0.0001% |
| Greene John | director | 7000 0.0072% | $349,930.00 | 1 | 0 | +20.43% |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
$477,065,869 | 34 | 82.05% | $6B | |
$151,136,640 | 31 | -1.41% | $3.95B |
| Increased Positions | 249 | +52.42% | 9M | +11.91% |
| Decreased Positions | 183 | -38.53% | 5M | -6.67% |
| New Positions | 94 | New | 5M | New |
| Sold Out Positions | 54 | Sold Out | 871,559 | Sold Out |
| Total Postitions | 541 | +13.89% | 76M | +5.24% |
| Ark Investment Management Llc | $526,246.00 | 10.3% | 9.79M | -395,617 | -3.88% | 2025-09-30 |
| Blackrock, Inc. | $379,086.00 | 7.42% | 7.05M | +983,787 | +16.22% | 2025-09-30 |
| Capital International Investors | $303,761.00 | 5.95% | 5.65M | +55,511 | +0.99% | 2025-09-30 |
| Orbis Allan Gray Ltd | $267,887.00 | 5.24% | 4.98M | +2M | +80.21% | 2025-09-30 |
| State Street Corp | $215,469.00 | 4.22% | 4.01M | +736,637 | +22.52% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $176,505.00 | 3.46% | 3.28M | -400,442 | -10.87% | 2025-09-30 |
| Vanguard Group Inc | $127,147.00 | 2.49% | 2.36M | +66,556 | +2.9% | 2025-09-30 |
| Ubs Group Ag | $125,771.00 | 2.46% | 2.34M | -504,521 | -17.74% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $116,341.00 | 2.28% | 2.16M | -251,163 | -10.4% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $116,341.00 | 2.28% | 2.16M | -250,596 | -10.38% | 2025-09-30 |